IPF News Briefs

medical technology

Telemedicine Valuable in Managing IPF During COVID-19 Outbreak

Telemedicine services during the COVID-19 pandemic lockdown significantly reduced the rate of hospitalization for patients with idiopathic pulmonary fibrosis (IPF) in Italy, according to findings published in Open Medicine. In response to the outbreak of COVID-19 in Italy, a tertiary referral center managing patients with IPF devised a telemedicine system to allow for continuous monitoring…

microarray

Study Identifies Five Hub Genes With Prognostic Value in IPF

Researchers identified 5 hub genes common to patients with idiopathic pulmonary fibrosis (IPF) and nonsmall cell lung cancer (NSCLC), which is a common complication of IPF, and published their results in Frontiers in Genetics. These results offer potential therapeutic targets for patients with IPF as well as insights into the underlying mechanisms of both diseases.…

doctors laboratory

New Phase 2 IPF Trial Evaluating Safety and Efficacy of AMB-05X

A new phase 2 clinical trial will evaluate the safety and efficacy of AMB-05X in patients with idiopathic pulmonary fibrosis (IPF). The randomized, placebo-controlled, multicenter study aims to enroll around 36 patients, aged 40 years and over. Participants will receive 6 doses of AMB-05X or placebo over a 24-week dosing period. The primary outcome measure…

chest CT

High Pulmonary Vascular Volume Correlates With Low DLCO in IPF

Researchers have discovered that pulmonary vascular volume is associated with the diffusing capacity for carbon monoxide (DLCO) and fibrotic score in idiopathic pulmonary fibrosis (IPF) and published their results in BMC Medical Imaging. IPF is a difficult disease to diagnose and usually requires multidisciplinary discussion. In addition, the disease course can be unpredictable. Hence, lung…

virtual med

First Patient Enrolled in New Digital Therapy Study for IPF

A new clinical study assessing the effect of digital cognitive behavioral therapy in patients with idiopathic pulmonary fibrosis (IPF) enrolled its first participant in its US pilot phase.  The study called COMPANION is sponsored by Vicore Pharma and is a fully digitalized, randomized, controlled parallel-group trial that aims to evaluate the impact of the digital…

lung cancer

Some Interleukins Could Be Sensitive Biomarkers for Lung Cancer-Related IPF

A study recently published in Therapeutics and Clinical Risk Management showed for the first time that some interleukins (IL) were significantly upregulated in patients with both idiopathic pulmonary fibrosis (IPF) and lung cancer, providing novel evidence for their use as sensitive biomarkers for the early diagnosis of patients with both pathologies. This study offers new…

gettyimages

New Radiomics Model Predicts Response to Antifibrotic Treatment in IPF

Researchers have discovered that radiomic features can be used to predict the therapeutic response of patients with idiopathic pulmonary fibrosis (IPF) to antifibrotic agents, as published in Diagnostics. IPF causes excessive fibrotic deposition in the lung parenchyma, eventually resulting in respiratory failure. This disease carries a poor prognosis, with mortality usually occurring within 5 years…

Chinese medicine

Baoyuan Decoction as a Potential Therapeutic Drug for IPF

Researchers revealed 8 potential treatment targets for idiopathic pulmonary fibrosis (IPF) in Baoyuan decoction (BYD), a traditional Chinese medicine that has antiapoptotic and antifibrosis effects as well as immunostimulatory activity, as published in Phytochemical Analysis. The researchers employed ultra-high performance liquid chromatography together with Orbitrap mass spectrometry and a network pharmacology analysis to reveal the…

questionnaire

Quality of Life Questionnaire Valuable in Predicting IPF Mortality

Quality-of-life (QoL) measured by the St. George’s Respiratory Questionnaire (SGRQ) could serve as a prognostic and mortality marker for patients with idiopathic pulmonary fibrosis (IPF), according to a new study published in Pulmonary Therapy. This prospective observational registry led by Wuyts enrolled 277 patients previously diagnosed with IPF. The data collected included healthcare resource use…

Next post in IPF News Briefs